Edition:
United Kingdom

Surmodics Inc (SRDX.OQ)

SRDX.OQ on NASDAQ Stock Exchange Global Select Market

72.75USD
9:00pm BST
Change (% chg)

$0.95 (+1.32%)
Prev Close
$71.80
Open
$71.85
Day's High
$72.85
Day's Low
$70.90
Volume
30,156
Avg. Vol
26,652
52-wk High
$74.10
52-wk Low
$25.00

Latest Key Developments (Source: Significant Developments)

Surmodics IVD Launches Breakthrough Matrixguard Diluent
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Surmodics Inc ::SURMODICS IVD LAUNCHES BREAKTHROUGH MATRIXGUARD™ DILUENT.SURMODICS INC - ANNOUNCED LAUNCH AND IMMEDIATE AVAILABILITY OF MATRIXGUARD DILUENT.  Full Article

Abbott And Surmodics Announce Agreement For Next-Generation Drug-Coated Balloon
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Abbott Laboratories ::ABBOTT AND SURMODICS ANNOUNCE AGREEMENT FOR NEXT-GENERATION DRUG-COATED BALLOON.SURMODICS INC - ‍PURSUANT TO TERMS OF AGREEMENT, SURMODICS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT​.SURMODICS INC - ‍PURSUANT TO TERMS OF AGREEMENT, CO MAY EARN AN ADDITIONAL $67 MILLION FOR VARIOUS PRODUCT DEVELOPMENT MILESTONES​.SURMODICS - ENTERED INTO AGREEMENT WHEREBY ABBOTT WILL HAVE EXCLUSIVE WORLDWIDE COMMERCIALIZATION RIGHTS FOR CO'S SURVEI DRUG-COATED BALLOON.SURMODICS INC - WILL BE RESPONSIBLE FOR MANUFACTURE AND SUPPLY OF CLINICAL AND COMMERCIAL QUANTITIES OF PRODUCT​.SURMODICS INC - ‍ABBOTT ALSO RECEIVED OPTIONS TO NEGOTIATE AGREEMENTS FOR CO'S BELOW-THE-KNEE AND AV FISTULA DRUG-COATED BALLOON PRODUCTS​.  Full Article

Surmodics Posts Q1 Adj. Earnings Per Share $0.10
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Surmodics Inc ::SURMODICS REPORTS FIRST QUARTER FISCAL 2018 RESULTS, UPDATES FISCAL 2018 GUIDANCE.Q1 NON-GAAP EARNINGS PER SHARE $0.10.Q1 GAAP LOSS PER SHARE $0.12.SEES FY 2018 REVENUE $72 MILLION TO $75 MILLION.TOTAL REVENUE FOR Q1 OF FISCAL 2018 WAS $17.0 MILLION, AS COMPARED WITH $17.8 MILLION IN PRIOR-YEAR PERIOD.AS A RESULT OF TAX CUTS AND JOBS ACT OF 2017, FISCAL 2018 Q1 NET LOSS INCLUDED A ONE-TIME TAX EXPENSE OF $1.2 MILLION, OR $0.09 PER SHARE.EXPECTS DILUTED LOSS IN RANGE OF $0.45 TO $0.70 PER SHARE IN 2018.2018 NON-GAAP DILUTED EARNINGS PER SHARE GUIDANCE RANGE IS NOW BETWEEN LOSS PER SHARE OF $0.20 TO EARNINGS PER SHARE OF $0.05.Q1 REVENUE VIEW $17.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Surmodics Receives FDA Clearance For Telemark Peripheral Support Microcatheter
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Surmodics Inc ::SURMODICS RECEIVES 510(K) CLEARANCE FOR TELEMARK™ CORONARY/PERIPHERAL SUPPORT MICROCATHETER FROM THE U.S. FOOD AND DRUG ADMINISTRATION.SURMODICS INC - CO IS MAKING PRODUCT AVAILABLE FOR U.S. DISTRIBUTION IN COMING MONTHS.  Full Article

Surmodics Q4 gaap earnings per share $0.03
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Surmodics Inc :Surmodics reports fourth quarter fiscal 2017 results and provides fiscal 2018 guidance.Q4 non-gaap earnings per share $0.18.Q4 gaap earnings per share $0.03.Q4 revenue $20.1 million versus i/b/e/s view $17.3 million.Q4 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S.Sees fy 2018 non-gaap loss per share $0.16 to $0.41.Sees fy 2018 loss per share $0.50 to $0.75.Sees fy 2018 revenue $72 million to $75 million.Fy2018 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.  Full Article

Surmodics says received FDA 510(K) and CE mark clearance​
Monday, 18 Sep 2017 

Sept 18 (Reuters) - Surmodics Inc ::Surmodics announces global approvals of .014" low-profile pta balloon dilation catheter.Surmodics Inc - ‍company received FDA 510(k) and CE mark clearance​.  Full Article

Surmodics Q3 non-GAAP earnings per share $0.09
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Surmodics Inc :Surmodics reports third quarter fiscal 2017 results and updates fiscal 2017 guidance.Q3 non-GAAP earnings per share $0.09.Q3 GAAP earnings per share $0.05.Sees FY 2017 revenue $70 million to $72 million.Q3 revenue $17.8 million versus I/B/E/S view $16 million.Sees FY 2017 non-GAAP earnings per share $0.29 to $0.39.Q3 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $0.19, revenue view $67.6 million -- Thomson Reuters I/B/E/S.Sees FY 2017 earnings per share $0.15 to $0.25.  Full Article

Surmodics Q2 non-gaap EPS $0.05
Thursday, 27 Apr 2017 

April 27 (Reuters) - Surmodics Inc :Surmodics reports second quarter fiscal 2017 results, updates fiscal 2017 financial guidance.Q2 gaap earnings per share $0.04.Sees fy 2017 revenue $65 million to $68 million.Q2 revenue rose 5 percent to $17.5 million.Sees fy 2017 non-gaap earnings per share $0.15 to $0.25.Sees fy 2017 loss per share $0.02 to $+0.08.Q2 non-gaap earnings per share $0.05.Surmodics inc says narrows financial outlook for fiscal 2017.Surmodics inc says medical device revenue was $12.7 million in q2 of fiscal 2017, an increase of 9.7% compared to year-ago period.  Full Article

Surmodics reports Q1 non-GAAP earnings per share $0.19
Thursday, 2 Feb 2017 

Surmodics Inc : Surmodics reports first quarter fiscal 2017 results . Surmodics reports first quarter fiscal 2017 results . Surmodics inc - raises revenue and eps guidance . Q1 revenue $17.8 million versus I/B/E/S view $15.8 million . Q1 non-GAAP earnings per share $0.19 . Surmodics Inc says remain on track to continue clinical evaluation of our surveil drug-coated balloon . Surmodics Inc- for 2017, company now expects gaap revenue to range from $64.0 million to $68.0 million, up from a previous range of $63.0 million to $67.0 million . Surmodics Inc - company now expects diluted earnings in range of loss per share of $0.07 to earnings of $0.08 per share for 2017 . Surmodics Inc sees non-GAAP earnings of $0.18 to $0.33 per share for 2017 .FY2017 earnings per share view $0.24, revenue view $65.3 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Surmodics Acquires Thrombectomy Technology Assets

* SURMODICS ACQUIRES THROMBECTOMY TECHNOLOGY ASSETS FROM EMBOLITECH, STRENGTHENING PERIPHERAL VASCULAR WHOLE-PRODUCT SOLUTIONS PORTFOLIO